New immunotherapy cocktail aims to fight High-Risk prostate cancer before and after surgery
NCT ID NCT06765902
First seen May 05, 2026 · Last updated May 15, 2026 · Updated 3 times
Summary
This study tested a combination of three immunotherapy drugs (N-803, ETBX-071, and M-CENK) given before and after prostate removal surgery in men with high-risk prostate cancer. The goal was to see if this approach could delay cancer recurrence and improve safety. However, the trial was withdrawn before enrolling any participants.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIGH-RISK PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.